HBM Holdings and Bristol Myers Squibb Sign Global Strategic Collaboration Agreement
I'm PortAI, I can summarize articles.
HBM Holdings Limited has signed a multi-year global strategic collaboration and license agreement with Bristol Myers Squibb to develop next-generation multi-specific antibodies. Harbour BioMed could receive up to $90 million in initial payments and up to $1.035 billion in milestone payments, plus tiered royalties. The original content was published by HBM Holdings Ltd. via the Hong Kong Stock Exchange on December 17, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments